According to new EP Vantage research, while employment in those companies characterized as “Big Pharma” decreased slightly in the period 2003-2013, biotechnology companies not traditionally considered part of that group compensated for the losses by more than doubling employment during the decade. The report shows how Big Pharma has changed through industry consolidation and dramatic restructuring, resulting in staff alterations that some had feared would show significant reductions. The mere 3-percent drop represented nearly 31,500 employees; with big biotech and specialty drug makers hiring 130,000, the losses were more than offset. EP Vantage Editor Lisa Urquhart said, “With the focus still on cost cutting in big pharma, if you want a long-term career in the industry, you might be better off with a smaller player.” See EPVantage News Release and PharmExec.com, June 18, 2014.